Treatment of Diabetic Macular Edema or Macular Edema Following Retinal Vein Occlusion Based on Repeated Injection of the Dexamethasone Intravitreal Implant: A Retrospective Real-World Analysis.
Clin Ophthalmol
; 17: 3177-3187, 2023.
Article
in En
| MEDLINE
| ID: mdl-37901284
ABSTRACT
Purpose:
To assess the "real world" utility of repeated injection with the dexamethasone intravitreal implant (DEX) in routine practice.Methods:
This was a retrospective, single-center analysis of consecutive patients with diabetic macular edema, or macular edema following retinal vein occlusion, treated with DEX. None had received prior intravitreal steroid treatment. DEX was implanted as per the manufacturer's instructions.Results:
Seventy-eight individuals (95 eyes) were included (50.0% female; mean age 68.1 ± 12.4 years; mean duration of macular edema 13.2 ± 12.9 months). Thirty-three eyes (34.7%) had received previous treatment with an anti-vascular endothelial growth factor (anti-VEGF) and/or laser. Thirty eyes (31.6%) underwent one round of DEX implantation; the remainder received 2-5 cycles (total 225 cycles). Initial DEX treatment led to significant increases in visual acuity (VA) at 6 weeks (mean change 4.6 letters; P=0.004). Greater VA improvements during the first treatment cycle were associated with inferior baseline VA (P=0.02), borderline associated with baseline central macular thickness (CMT; P=0.06), and independent of prior anti-VEGF treatment (P=0.39). In an analysis of all DEX injections, VA improvements were robust across cycles 1 and 2 but reduced in cycle 3 (P=0.03). CMT improvements did not differ based on injection number (P=0.20). Increases in intraocular pressure (IOP) were largest over the first 6 weeks (but rebounded towards baseline more rapidly) in cycle 1 versus cycles 2 and 3 (P<0.001). IOP rises were typically manageable with topical medications.Conclusion:
This analysis confirms the broad utility of DEX and may inform decision-making in routine practice.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Clin Ophthalmol
Year:
2023
Document type:
Article
Affiliation country:
United kingdom